Significance of post-progression therapy after tyrosine kinase inhibitors for advanced hepatocellular carcinoma.
hepatocellular carcinoma
post‐progression therapy
tyrosine kinase inhibitor
Journal
JGH open : an open access journal of gastroenterology and hepatology
ISSN: 2397-9070
Titre abrégé: JGH Open
Pays: Australia
ID NLM: 101730833
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
14
02
2022
revised:
07
05
2022
accepted:
09
05
2022
entrez:
1
7
2022
pubmed:
2
7
2022
medline:
2
7
2022
Statut:
epublish
Résumé
Molecular-targeted therapies such as sorafenib and lenvatinib have long been used as first-line treatment for advanced hepatocellular carcinoma (aHCC). However, adverse events or limited therapeutic effects may necessitate the change to another therapeutic option, known as post-progression therapy. To investigate the significance of post-progression therapy, we analyzed the outcomes of aHCC patients following first-line molecular-targeted therapy in a real-world study. This retrospective, multicenter study involved patients with aHCC who received sorafenib or lenvatinib as first-line therapy between January 2011 and September 2021. In total, 513 patients were analyzed: 309 treated with sorafenib and 204 with lenvatinib. The overall response and disease control rates were 15 and 50%, respectively, in the sorafenib group and 30 and 75%, respectively, in the lenvatinib group ( The introduction of newer drugs for post-progression therapy is expected to prolong survival. ICI-based regimens appear to be effective after lenvatinib.
Sections du résumé
Background and Aim
UNASSIGNED
Molecular-targeted therapies such as sorafenib and lenvatinib have long been used as first-line treatment for advanced hepatocellular carcinoma (aHCC). However, adverse events or limited therapeutic effects may necessitate the change to another therapeutic option, known as post-progression therapy. To investigate the significance of post-progression therapy, we analyzed the outcomes of aHCC patients following first-line molecular-targeted therapy in a real-world study.
Methods
UNASSIGNED
This retrospective, multicenter study involved patients with aHCC who received sorafenib or lenvatinib as first-line therapy between January 2011 and September 2021.
Results
UNASSIGNED
In total, 513 patients were analyzed: 309 treated with sorafenib and 204 with lenvatinib. The overall response and disease control rates were 15 and 50%, respectively, in the sorafenib group and 30 and 75%, respectively, in the lenvatinib group (
Conclusion
UNASSIGNED
The introduction of newer drugs for post-progression therapy is expected to prolong survival. ICI-based regimens appear to be effective after lenvatinib.
Identifiants
pubmed: 35774348
doi: 10.1002/jgh3.12772
pii: JGH312772
pmc: PMC9218537
doi:
Types de publication
Journal Article
Langues
eng
Pagination
427-433Informations de copyright
© 2022 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Liver Cancer. 2020 Jan;9(1):73-83
pubmed: 32071911
Liver Int. 2021 Nov 15;:
pubmed: 34780081
Liver Cancer. 2020 Jan;9(1):93-104
pubmed: 32071913
World J Hepatol. 2021 Mar 27;13(3):384-392
pubmed: 33815680
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
Lancet Oncol. 2009 Jan;10(1):35-43
pubmed: 19058754
Cancer Manag Res. 2021 Dec 24;13:9379-9389
pubmed: 34992463
J Clin Med. 2020 Dec 21;9(12):
pubmed: 33371271
Clin J Gastroenterol. 2022 Feb;15(1):177-184
pubmed: 34811701
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Lancet Oncol. 2019 Feb;20(2):282-296
pubmed: 30665869
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Medicine (Baltimore). 2020 Oct 16;99(42):e22782
pubmed: 33080748
Front Oncol. 2021 Oct 25;11:737767
pubmed: 34760699
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850